? DEVELOPMENTAL FUNDS Duke Cancer Institute (DCI) Developmental Funds are instrumental to the DCI strategic research priorities and provide resources to augment its Research Programs and Strategic Initiatives. In the current grant cycle, DCI Developmental Funds, comprised of CCSG, institutional and philanthropic funds, have supported collaborative, translational and novel high-impact pilot projects, recruitment of new investigators, and emerging technologies that promote innovative new research of DCI members. The DCI supports multiple Pilot Grant Programs, including one which alternatively emphasizes collaborative projects (intra-programmatic, inter-programmatic, population science) and translational projects (laboratory discoveries into diagnostic, prognostic, or therapeutic applications), solicited through a ?Request for Applications? (RFA) twice each year. Additionally, DCI has targeted Pilot Grant Programs each year focused on strategic topics, which are supported by multiple sources, including institutional and philanthropic funds. The strategic areas of focus in the current funding period are: i) Cancer Control; ii) Cancer and the Environment; iii) Supportive Care and Survivorship; iv) Comparative Oncology (an external collaboration with the College of Veterinary Medicine at NC State University); v) Solid Tumor Brain Metastasis; vi) BRCA-associated cancers; and vii) collaboration between cancer and engineering research. Faculty recruitment that represents a strategic investment as outlined by the DCI strategic plan and DCI senior leaders are eligible for Developmental Funds as part of their initial recruitment package, or within three years of their faculty appointment. The recruitment funds are made available at any time throughout the year to maintain optimal flexibility in faculty recruitment. Developmental Funds are also available through solicitations offered twice per year for support of a new service line, creation and implementation of a new technique, or a technology investment that enhances existing shared resource services and expands the research tools of DCI investigators. All applications for DCI Developmental Funds are reviewed by the Scientific Review Committee (SRC) or the Shared Resource Oversight Committee (SROC). The DCI Steering Committee is charged with strategic oversight of the DCI Developmental Funds. The final funding decisions are based on assessment of availability of funds and prioritization of strategic investments, with approval by the DCI Executive Director. During this funding period, DCI Developmental Funds were used to support pilot and collaborative projects, recruitment of faculty, and shared resource investment. The $2.9M of CCSG Developmental Funds were augmented by additional $29.4M of institutional/philanthropic funds in all three categories. In the next funding period, CCSG investments will continue to be augmented by institutional and philanthropic funds to advance DCI scientific discoveries, support collaborative working groups and invest in shared resources to ensure DCI members have the necessary services and technologies to achieve the DCI mission and vision.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA014236-46
Application #
9853612
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
46
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784

Showing the most recent 10 out of 513 publications